Department of Respiratory Medicine, Galway University Hospital, National University of Ireland Galway, Galway, Ireland,
Lung. 2013 Dec;191(6):663-8. doi: 10.1007/s00408-013-9503-3. Epub 2013 Sep 13.
Although oropharyngeal candidiasis is associated with inhaled corticosteroid (ICS) usage, there is sparse data on the prevalence of posterior pharyngeal candidiasis in those without any detectable oral candidiasis on clinical examination. We systematically investigated the relationship between oral candidiasis on clinical examination and the presence of posterior pharyngeal candidiasis at bronchoscopy.
We conducted a cross-sectional study on a convenience sample of 100 patients undergoing bronchoscopy at our institution. Patients were assessed for symptoms of and risk factors for candida infection and had an examination of their oropharynx for evidence of candidiasis before bronchoscopy. They subsequently had a detailed assessment for posterior candidiasis at bronchoscopy. We performed a posteriori subgroup analysis, which focused solely on those patients on ICS maintenance therapy.
Median age was 54.7 (27-84) years, and 55 patients were male; 47 % of patients were on ICS, and 20 % of this cohort received recent oral corticosteroids. Twenty-eight percent of this convenience sample had posterior pharyngeal candidiasis; however, only 10.7 % (3/28) of these patients had clinically detectable oral candidiasis on clinical examination before bronchoscopy. Factors that were independently associated with the presence of pharyngeal candidiasis at bronchoscopy were OR (95 % CI) ICS usage 6.9 (2.5-19.2), particularly fluticasone usage 6.8 (2.62-17.9) and the presence of dysphonia 3.2 (1.3-8.0). In the subgroup analysis of ICS usage, posterior pharyngeal candidiasis was correlated with the presence of dysphonia but was not independently associated with fluticasone or budesonide dosage.
This study demonstrates that posterior pharyngeal candidiasis in the absence of clinically overt oral candidiasis is frequent amongst ICS users. A history of ICS use, particularly fluticasone usage, as well as the presence of dysphonia are associated with posterior pharyngeal candidiasis at bronchoscopy, even in the absence of clinically overt oral involvement.
虽然口咽念珠菌病与吸入性皮质类固醇(ICS)的使用有关,但在临床上没有发现任何口腔念珠菌病的情况下,后咽部念珠菌病的患病率数据很少。我们系统地研究了临床检查中口腔念珠菌病与支气管镜检查时后咽部念珠菌病之间的关系。
我们对在我院进行支气管镜检查的 100 例患者进行了一项横断面研究。对患者进行了念珠菌感染的症状和危险因素评估,并在支气管镜检查前对其口咽部进行了念珠菌检查。随后,在支气管镜检查时对后咽部进行了详细评估。我们进行了事后亚组分析,该分析仅专注于接受 ICS 维持治疗的患者。
中位年龄为 54.7(27-84)岁,55 例患者为男性;47%的患者使用 ICS,其中 20%的患者在最近使用了口服皮质类固醇。该便利样本中有 28%的患者患有后咽部念珠菌病;然而,只有 10.7%(3/28)的患者在支气管镜检查前的临床检查中发现了可检测到的口腔念珠菌病。与支气管镜检查时存在咽部念珠菌病相关的独立因素是 OR(95%CI)ICS 使用率 6.9(2.5-19.2),特别是氟替卡松使用率 6.8(2.62-17.9)和声音嘶哑的存在 3.2(1.3-8.0)。在 ICS 使用的亚组分析中,后咽部念珠菌病与声音嘶哑有关,但与氟替卡松或布地奈德剂量无关。
本研究表明,在没有明显的临床口腔念珠菌病的情况下,ICS 使用者中经常出现后咽部念珠菌病。ICS 使用史,特别是氟替卡松使用史,以及声音嘶哑与支气管镜检查时的后咽部念珠菌病有关,即使在没有明显的临床口腔受累的情况下也是如此。